On July 2, 2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the public release of the animation for leronlimab in immuno-oncology. Click here (https://www.dropbox.com/s/2uu5xp6fffzpwew/CytoDyn%20Leronlimab.mp4?dl=0) to view the animation. CytoDyn is encouraged by the potential of leronlimab to positively influence the tumor microenvironment by inhibiting T-reg infiltration, conversion of M2 macrophages (protumor macrophages) into M1 macrophages (antitumor macrophages), decreasing tumor angiogenesis, and inhibiting metastasis through CCR5 overexpression. CytoDyn is currently exploring the efficacy of leronlimab for several immuno-oncology indications, including metastatic triple-negative breast cancer, a mechanism of action basket trial for 22 solid tumors, and a Phase 2 combination therapy for metastatic colorectal cancer. The FDA has granted leronlimab Fast Track designation for metastatic triple-negative breast cancer. “We appreciate the work of Nucleus Medical Media to capture the potential benefits of leronlimab in the tumor microenvironment. The control of the tumor microenvironment is critical in the ultimate determination of clinical patient outcomes. We believe leronlimab may help leverage the immune system’s natural ability to fight cancer. Leronlimab’s safety profile and potential synergistic effects with current oncology treatments may prove to be an exciting opportunity within immuno-oncology,” said Scott A. Kelly, MD, Chief Medical Officer and Chairman of the Board of CytoDyn. CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S.Login Or Register To Read Full Story